JV-394

N/A

Report date: 2026/02/24 20:00:16

Base Information

Drug NameJV-394
Drug Alias NameAutologous Anti-CD94 Chimeric Antigen Receptor T Cell Therapy (The University Of Texas MD Anderson Cancer Center)JV-394
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD94T lymphocyte replacements
TargetsNatural killer cells antigen CD94
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A